| Literature DB >> 34177854 |
Elena Carra1, Simone Russo1, Alessia Micheli1, Chiara Garbarino1, Matteo Ricchi1, Federica Bergamini1, Patrizia Bassi1, Alice Prosperi1, Silvia Piva2, Monica Cricca3,4, Roberta Schiavo5, Giuseppe Merialdi1, Andrea Serraino2, Norma Arrigoni1.
Abstract
Streptococcus agalactiae (group B Streptococcus, GBS) is one of the most important agents of bovine mastitis and causes remarkable direct and indirect economic losses to the livestock sector. Moreover, this species can cause severe human diseases in susceptible individuals. To investigate the zoonotic potential of S. agalactiae, 203 sympatric isolates from both humans and cattle, isolated in the same time frame (2018) and in the same geographic area (Emilia Romagna region, Northern Italy), were characterized by molecular capsular typing (MCT), pilus island typing (PI), and multi-locus sequence typing (MLST). In addition, antibiotic-resistant phenotypes were investigated. The distribution of the allelic profiles obtained by combining the three genotyping methods (MCT-PI-MLST) resulted in 64 possible genotypes, with greater genetic variability among the human compared to the bovine isolates. Although the combined methods had a high discriminatory power (>96,2%), five genotypes were observed in both species (20,9% of the total isolates). Furthermore, some of these strains shared the same antibiotic resistance profiles. The finding of human and bovine isolates with common genotypes and antibiotic resistance profiles supports the hypothesis of interspecies transmission of S. agalactiae between bovines and humans.Entities:
Keywords: MLST; Streptococcus agalactiae; antimicrobial resistance; bovines; genotyping; humans; molecular capsular typing; pilus island
Year: 2021 PMID: 34177854 PMCID: PMC8226232 DOI: 10.3389/fmicb.2021.673126
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Origin and characteristics of Streptococcus agalactiae isolates included in this study.
| Host | Number of isolates | Geographical origin (province) | Number of herds | Number of MCT-PI- MLST profiles |
| Bovine | 53 | Parma | 28 | 18* |
| 20 | Reggio Emilia | 9 | 7 | |
| 15 | Piacenza | 7 | 8 | |
| 12 | Modena | 4 | 4 | |
| 3 | Bologna | 1 | 1 | |
| TOTAL | ||||
| Humans | 49 | Piacenza | 1 | 24* |
| 51 | Bologna | 1 | 27 | |
| TOTAL | ||||
FIGURE 1Pilus island typing. The expected fragment sizes were 394, 243, and 519 bp for PI-1, PI-2a, or PI-2b, respectively. The image shows the pilus island profiles obtained for the ATCC 13813 strain, and for the human 1–109 (1) and 2–109 (2) isolates.
Results of the molecular capsular typing, pilus island typing, and multi-locus sequence typing of 201 Streptococcus agalactiae isolates.
FIGURE 2Minimum spanning tree obtained by global eBurst analysis using PHYLOVIZ software. This shows the distribution of host species across clusters of Streptococcus agalactiae sequence types (STs) obtained in the present study. Each circle represents an ST. The size of the circle and its colored segments are proportional to the number and origin of isolates, where pink refers to humans and blue refers to bovines, respectively. Clusters, including single- and double-locus variants, are indicated by the corresponding clonal complex (CC).
FIGURE 3Neighbor-joining (NJ) tree. Genetic relationships among the 45 S. agalactiae sequence types (STs) obtained in the present study were inferred with MEGA5 software [14]. Evolutionary distances were calculated using the p-distance method, which considers the number of different nucleotides out of the total (3,456). A NJ tree with 1,000 bootstrap replications was constructed. The clonal complexes (CCs) obtained by the global eBURST analysis are reported.
Molecular capsular typing and sequence types of the bovine and human resistant isolates.
| Bovine isolates | Human isolates | |||
| MCT | ST | MCT | ST | |
| Erythromycin | Ia | 12, 1,366 | ||
| Ib | 1 | Ib | 10 | |
| II | 591 (2) | II | 19, 22, 28 | |
| V | 1, 498 (3) | V | 1 (7), 19, 109, 498, NT | |
| NT | 2 | |||
| Kanamycin | All strains | All strains | ||
| Pirlimycin | Ib | 1 | Ib | 10 |
| III | 1,397 | II | 19, 22 | |
| IV | 459, 1,363 | |||
| V | 1 (2), 498 | V | 1 (7), 19, NT | |
| NT | 2 (2) | |||
| Sulfisoxazole | Ia | 4, 103 (4), 591, 1002, 1366 | Ia | 4, 23 (8), 55, 144 |
| Ib | 8, 12 | |||
| II | 591 (7) | II | 10, 12, 19 (2), 22, 28 (4), 932 | |
| III | 23 (2) | III | 17 (10), 19 (2) | |
| IV | 297 (3), 1363, 1365 | IV | 196 | |
| V | 1 | V | 1 (2), 19 (2), 26, 498, 832, NT | |
| Tetracycline | Ia | 12, 23, 103 (11), 314 (2), 1002 (2) | Ia | 23 (4), 24, 498 |
| Ib | 1, 6 (3) | Ib | 12 | |
| II | 1, 12, 19 (2), 22, 28 (2), 569, 932 | |||
| III | 27, NT | III | 17 (5), 529 (2) | |
| IV | 297, 459, 1363, 1398, | IV | 196 (2) | |
| V | 498 (3) | V | 1 (4), 19, 26 (2), 498, 529, 832, NT | |
| NT | 2 (2) | |||
| Trimethoprim – sulfamethoxazole | V | 1 | ||
Antimicrobial susceptibility testing.
| Bovine isolates not susceptible (intermediated or resistant) | Human isolates not susceptible (intermediated or resistant) | |
| Amoxicillin-clavulanic acid | 0 | 0 |
| Ampicillin | 0 | 0 |
| Cephalothin | 0 | 0 |
| Ceftiofur | 0 | 0 |
| Erythromycin | 11 (10.7%) | 15 (15%) |
| Kanamycin | 103 (100%) | 100 (100%) |
| Penicillin G | 0 | 0 |
| Pirlimycin | 9 (8.7%) | 12 (12%) |
| Rifampicin | 0 | 0 |
| Sulfisoxazole | 23 (22.3%) | 44 (44%) |
| Tetracycline | 32 (31.1%) | 36 (36%) |
| Trimethoprim – sulfamethoxazole | 1 (1.0%) | 0 |